New

Global ETF Survey 2026: Answer now →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

The ETF Industry Is Evolving Fast

From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.

Global ETF Survey 2026
ETF IssuersInvescoPJP
PJP

Invesco Dynamic Pharmaceuticals ETF

The PJP Exchange Traded Fund (ETF) is provided by Invesco. It is built to track an index: Dynamic Pharmaceutical Intellidex Index. The PJP ETF provides physical exposure, so by buying it you actually own parts of all the 28 underlying holdings. This share class generates a stream of income by distributing dividends.

Advertisement

Advertisement

$118.78
-$0.01 (-0.01%) today
2:18 PM 07/23/26 Open
1D price range
$118.78$118.78
52W price range
$80.89$122.26
YTD Perf.
+14.27%
YTD Flows
Annualized volatility
Fund AuM
€383M
Share class AuM
€383M
TTM Yield
Tracking Error
Tracking Difference
ISIN
US46137V6627
TER
0.57%
Inception date
6/23/2005
Issuer
Replication method
Dividend policy
Compare similar ETFs
API
PerformanceDec 31, 2025 - Jul 22, 2026
-5%0%5%10%15%JANMARMAYJUL
Flows
Join for free to unlock
Data as of 06/30/26
Healthcare
100.00%
Latest PJP news

No content available for this fund

FAQ about PJP

PJP is a Passive ETF. This ETF provides exposure to Equally Weighted US Pharmaceuticals Equities.
PJP tracks the Dynamic Pharmaceutical Intellidex Total Return Index - USD, through a full replication replication method.
PJP carries a total expense ratio (TER) of 0.57%, indicating the annual cost for holding the fund.
PJP was introduced to the market on June 23, 2005. It trades on United States
Invesco Dynamic Pharmaceuticals ETF, PJP, is provided by Invesco. Learn more about Invesco here.
PJP oversees €383M in assets as of July 22, 2026.
PJP follows a distributing dividend policy, meaning it pays out income to investors. As of July 22, 2026, its 12-month trailing yield was 0.90%.
As of June 30, 2026, PJP has significant geographic allocations in USA and Ireland.
As of June 30, 2026, PJP focuses largely on Healthcare.
As of June 30, 2026, PJP holds 28 positions in its portfolio, with 64.89% of assets concentrated in its top 15 holdings.
As of June 30, 2026, PJP top three holdings include AbbVie, Inc., Eli Lilly & Co. and Johnson & Johnson.
The base currency of PJP is USD.
Data as of 06/30/26
AbbVie, Inc.
5.65%
Eli Lilly & Co.
5.39%
Johnson & Johnson
5.26%
Abbott Laboratories
5.16%
Merck & Co., Inc.
5.11%
Amgen, Inc.
5.07%
Gilead Sciences, Inc.
4.54%
Pfizer Inc.
4.46%
Corcept Therapeutics, Inc.
3.87%
Amneal Pharmaceuticals, Inc.
3.60%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight